Trial Profile
Phase I Trial of OSI-774 and CPT-11 in Patients With Advanced Solid Tumors.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Sep 2023
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary) ; Irinotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacodynamics; Pharmacogenomic; Pharmacokinetics; Therapeutic Use
- 23 Aug 2023 Planned End Date changed from 1 Jun 2009 to 22 Aug 2024.
- 23 Aug 2023 Planned End Date changed from 1 Jun 2009 to 22 Aug 2024.
- 23 Aug 2023 Planned End Date changed from 1 Jun 2009 to 22 Aug 2024.